Literature DB >> 18079279

Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators.

Viola Tamasi1, Kristy K Michael Miller, Sharon L Ripp, Ermin Vila, Thomas E Geoghagen, Russell A Prough.   

Abstract

Dehydroepiandrosterone (DHEA), a C19 human adrenal steroid, activates peroxisome proliferator-activated receptor alpha (PPARalpha) in vivo but does not ligand-activate PPARalpha in transient transfection experiments. We demonstrate that DHEA regulates PPARalpha action by altering both the levels and phosphorylation status of the receptor. Human hepatoma cells (HepG2) were transiently transfected with the expression plasmid encoding PPARalpha and a plasmid containing two copies of fatty acyl coenzyme oxidase (FACO) peroxisome-proliferator activated receptor responsive element consensus oligonucleotide in a luciferase reporter gene. Nafenopin treatment increased reporter gene activity in this system, whereas DHEA treatment did not. Okadaic acid significantly decreased nafenopin-induced reporter activity in a concentration-dependent manner. Okadaic acid treatment of primary rat hepatocytes decreased both DHEA- and nafenopin-induced FACO activity in primary rat hepatocytes. DHEA induced both PPARalpha mRNA and protein levels, as well as PP2A message in primary rat hepatocytes. Western blot analysis showed that the serines at positions 12 and 21 were rapidly dephosphorylated upon treatment with DHEA and nafenopin. Results using specific protein phosphatase inhibitors suggested that protein phosphatase 2A (PP2A) is responsible for DHEA action, and protein phosphatase 1 might be involved in nafenopin induction. Mutation of serines at position 6, 12, and 21 to an uncharged alanine residue significantly increased transcriptional activity, whereas mutation to negative charged aspartate residues (mimicking receptor phosphorylation) decreased transcriptional activity. DHEA action involves induction of PPARalpha mRNA and protein levels as well as increased PPARalpha transcriptional activity through decreasing receptor phosphorylation at serines in the AF1 region.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079279      PMCID: PMC2423814          DOI: 10.1124/mol.107.036780

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  38 in total

Review 1.  CAR, driving into the future.

Authors:  Karen Swales; Masahiko Negishi
Journal:  Mol Endocrinol       Date:  2004-02-26

2.  Regulation of peroxisome proliferator-activated receptor alpha by protein kinase C.

Authors:  Joshua P Gray; Katherine A Burns; Tara L Leas; Gary H Perdew; John P Vanden Heuvel
Journal:  Biochemistry       Date:  2005-08-02       Impact factor: 3.162

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors.

Authors:  K C Falkner; J A Pinaire; G H Xiao; T E Geoghegan; R A Prough
Journal:  Mol Pharmacol       Date:  2001-09       Impact factor: 4.436

Review 5.  Peroxisome proliferator-activated receptors: insight into multiple cellular functions.

Authors:  P Escher; W Wahli
Journal:  Mutat Res       Date:  2000-03-17       Impact factor: 2.433

6.  Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma.

Authors:  Jonathan M Shipley; David J Waxman
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

7.  Inhibitors of protein phosphatases 1 and 2A differentially prevent intrinsic and extrinsic apoptosis pathways.

Authors:  Kathryn Chatfield; Alan Eastman
Journal:  Biochem Biophys Res Commun       Date:  2004-10-29       Impact factor: 3.575

8.  Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation.

Authors:  Olivia S Gardner; Brian J Dewar; H Shelton Earp; James M Samet; Lee M Graves
Journal:  J Biol Chem       Date:  2003-09-09       Impact factor: 5.157

Review 9.  Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation.

Authors:  Christophe Blanquart; Olivier Barbier; Jean Charles Fruchart; Bart Staels; Corine Glineur
Journal:  J Steroid Biochem Mol Biol       Date:  2003-06       Impact factor: 4.292

10.  Regulation of CYP2C11 by dehydroepiandrosterone and peroxisome proliferators: identification of the negative regulatory region of the gene.

Authors:  Sharon L Ripp; K Cameron Falkner; Mary L Pendleton; Viola Tamasi; Russell A Prough
Journal:  Mol Pharmacol       Date:  2003-07       Impact factor: 4.436

View more
  10 in total

1.  Inflammation-associated upregulation of the sulfated steroid transporter Slc10a6 in mouse liver and macrophage cell lines.

Authors:  Astrid Kosters; Demesew F Abebe; Julio C Felix; Paul A Dawson; Saul J Karpen
Journal:  Hepatol Res       Date:  2015-11-19       Impact factor: 4.288

Review 2.  Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.

Authors:  Rebecca B Riggins; Mary M Mazzotta; Omar Z Maniya; Robert Clarke
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

3.  Dehydroepiandrosterone replacement therapy in older adults improves indices of arterial stiffness.

Authors:  Edward P Weiss; Dennis T Villareal; Ali A Ehsani; Luigi Fontana; John O Holloszy
Journal:  Aging Cell       Date:  2012-08-01       Impact factor: 9.304

4.  Ras/mitogen-activated protein kinase (MAPK) signaling modulates protein stability and cell surface expression of scavenger receptor SR-BI.

Authors:  Peta Wood; Vishwaroop Mulay; Masoud Darabi; Karen Cecilia Chan; Joerg Heeren; Albert Pol; Gilles Lambert; Kerry-Anne Rye; Carlos Enrich; Thomas Grewal
Journal:  J Biol Chem       Date:  2011-04-27       Impact factor: 5.157

Review 5.  Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS).

Authors:  Nicole Maninger; Owen M Wolkowitz; Victor I Reus; Elissa S Epel; Synthia H Mellon
Journal:  Front Neuroendocrinol       Date:  2008-12-03       Impact factor: 8.606

6.  5-Androstene-3β,7β,17β-triol (β-AET) slows thermal injury induced osteopenia in mice: relation to aging and osteoporosis.

Authors:  Ajay K Malik; Sophia Khaldoyanidi; Dominick L Auci; Scott C Miller; Clarence N Ahlem; Christopher L Reading; Theodore Page; James M Frincke
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

7.  Steroidogenic control of liver metabolism through a nuclear receptor-network.

Authors:  Alexandra Milona; Vittoria Massafra; Harmjan Vos; Jyoti Naik; Natalia Artigas; Helen A B Paterson; Ingrid T G W Bijsmans; Ellen C L Willemsen; Jose M Ramos Pittol; Irene Miguel-Aliaga; Piter Bosma; Boudewijn M T Burgering; Catherine Williamson; Santiago Vernia; Waljit S Dhillo; Saskia W C van Mil; Bryn M Owen
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 8.  Reprogramming of glucose metabolism of cumulus cells and oocytes and its therapeutic significance.

Authors:  Shogo Imanaka; Hiroshi Shigetomi; Hiroshi Kobayashi
Journal:  Reprod Sci       Date:  2021-03-05       Impact factor: 3.060

9.  Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.

Authors:  Longxin Qiu; Jianhui Lin; Miao Ying; Weiqiang Chen; Jinmei Yang; Tiantian Deng; Jinfeng Chen; Duanyu Shi; James Y Yang
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

10.  Spinal Cord Injury Reduces Serum Levels of Fibroblast Growth Factor-21 and Impairs Its Signaling Pathways in Liver and Adipose Tissue in Mice.

Authors:  Xin-Hua Liu; Zachary A Graham; Lauren Harlow; Jiangping Pan; Daniella Azulai; William A Bauman; Joshua Yarrow; Christopher P Cardozo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-11       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.